This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla

Loading...
Loading...

An investment in Ocugen Inc OCGN one year ago is undoubtedly a sight for sore eyes.

Since January 2021, Ocugen stock's year-to-date return has outperformed a number of the world’s most popular companies: AMC Entertainment Holdings Inc AMC, Snap Inc SNAP, Apple Inc AAPL and Tesla Inc TSLA

Ocugen is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure diseases that cause blindness. Ocugen’s pipeline offers a diversified ophthalmology portfolio including novel gene therapies, biologics and small molecules, and targets a broad range of high-need retinal and ocular surface diseases.

Ocugen also has a strategic partnership with Bharat Biotech for the commercialization of COVAXIN in the U.S. market. The company is headquartered in Malvern, Pennsylvania.

According to data from Benzinga Pro, Ocugen has a total share float of 193.50 million, of which 54.18 million shares are sold short, representing 27.94% of shares sold short.

Here's how the returns break down from September 2020 to present: 

  • Apple is up from $112.82 a share to $154.30 for a return of 36.77%
  • Tesla is up from $330.21 a share to $733.57 for a return of 122.15%
  • Snap is up from $22.69 a share to $75.08 for a return of 230.89%
  • AMC is up from $6.42 a share to $44.02 for a return of 585.67%
  • And finally, Ocugen is up from $0.33 a share to $7.43 for a return of 2,151.52%

 

Loading...
Loading...
Posted In: BiotechHealth CareSmall CapMoversTrading IdeasGeneralBharat Biotech
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...